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Abstract
Background Phosphodiesterase 5 (PDE5) inhibitors increase
cyclic guanosine monophosphate (cGMP) concentrations in
the intracellular pathway activated byN-methyl-D-aspartic acid
receptors which is believed to mediate long-term potentiation
and memory consolidation. The PDE5 inhibitor sildenafil has
been shown to enhance memory in animal models. In
addition, neuronal nitric oxide synthase, another component
of the NMDA/nitric oxide/cGMP intracellular pathway, has
been reported to be dysregulated in schizophrenia patients.
Materials and methods Seventeen adult schizophrenia
outpatients treated with a stable dose of antipsychotic
received a single oral dose of placebo, sildenafil 50 mg,
and sildenafil 100 mg in random order with a 48-h interval
between administrations. Psychiatric symptom ratings and a
cognitive battery were performed at baseline and 1 hour
following each administration of the study drug. In addition,
memory consolidation was examined by testing recall 48
h later, prior to the next administration of the study drug.
Results Fifteen subjects completed all three treatment
conditions. One subject developed irritability and required
hospitalization 2 days after receiving sildenafil 100 mg.
Neither dose of sildenafil significantly affected cognitive
performance or symptom ratings compared to the placebo.
Conclusion Despite evidence for cognitive-enhancing
effects of sildenafil in animal models, the strategy for
treating putative NMDA receptor-mediated memory deficits
in schizophrenia with sildenafil 50 and 100 mg was not
successful. It is possible that the doses used in this study
were not optimal or that repeated dosing may be necessary
to achieve therapeutic effects. Agents under development
that inhibit other subtypes of PDE remain promising for
schizophrenia and dementia.
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Introduction
Hypoactivity of N-methyl-D-aspartate (NMDA) receptors has
been identified as a possible mechanism underlying patho-
logical symptoms and cognitive deficits in schizophrenia
(Goff and Coyle 2001). Agents that enhance NMDA activity
have produced mixed results in schizophrenia, with im-
provement of negative symptoms in some but not all trials
(Buchanan et al. 2007; Tuominen et al. 2005) and largely
negative effects on measures of learning and memory
(Buchanan et al. 2007; Goff et al. 1999, 2005). Animal
studies have demonstrated that tolerance rapidly develops for
the cognitive-enhancing effects of the glycine site partial
agonist, D-cycloserine, following repeated dosing (Parnas
et al. 2005; Quartermain et al. 1994), possibly reflecting the
trafficking of NMDA receptors from cell membrane to the
intracellular compartment in response to increased activity at
the glycine site (Nong et al. 2003).
Targeting pharmacological treatments at points “down-
stream” from the NMDA receptor, at the level of
intracellular biochemical pathways, represents an alterna-
tive strategy to avoid the development of tolerance.
Activation of NMDA receptors results in calcium influx
into the cell, which binds to calmodulin and activates
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neuronal nitric oxide (NO) synthase (NOS), thereby increas-
ing intracellular NO concentrations. NO activates guanylyl
cyclase, which increases cyclic guanine monphosphate
(cGMP; Fig. 1). This “NMDA–NO–cGMP intracellular
pathway” is believed to mediate long-term potentiation and
memory consolidation (Erceg et al. 2005; Prickaerts et al.
2002a; Yamada et al. 1996). Phosphodiesterase 5 (PDE5)
inhibitors act to increase cGMP without directly affecting
NMDA receptors. Targeting PDE5 to increase cGMP might
selectively correct deficits resulting from NMDA receptor
hypofunction without the development of tachyphylaxis.
Three PDE5 inhibitors are currently approved for the
treatment of erectile dysfunction (sildenafil, tadalafil, and
vardenafil; Rosen and Kostis 2003). These agents readily
cross the blood–brain barrier, are very well tolerated, and
recently have been found to have cognitive-enhancing and
neuroprotective effects in rodents (Prickaerts et al. 2004;
Zhang et al. 2002). PDE5 has been identified in rat brain,
including the cortex and hippocampus (van Staveren et al.
2005; Van Staveren et al. 2003), and subchronic administra-
tion of sildenafil has been demonstrated to increase cortical
cGMP levels (Prickaerts et al. 2002b; Zhang et al. 2002).
Intrahippocampal administration of an inhibitor of
guanylate cyclase (to selectively lower cGMP concentrations)
impaired learning of inhibitory avoidance in rats (Bernabeu
et al. 1996), whereas administration of an analog of cGMP
facilitated memory consolidation (Bernabeu et al. 1997).
Sildenafil 3 and 10 mg/kg. significantly improved retention
at 24 h of an object recognition task in rats (Prickaerts et al.
2002b), and sildenafil 3 mg/kg improved retention at 48 h of
a passive avoidance task utilizing an aversive stimulus
(Baratti and Boccia 1999). Sildenafil 2, 4, and 8 mg/kg also
dose-dependently improved acquisition of maze learning in
mice (Singh and Parle 2003). Sildenafil reversed cognitive
deficits in rats produced by electroconvulsive therapy (Patil
et al. 2006), diabetes (Patil et al. 2006), anticholinergics
(Devan et al. 2004), hyperammonemia (Erceg et al. 2005),
and NOS inhibitors (Devan et al. 2006, 2007). Memory
enhancement occurred when sildenafil was administered
before training or up to 3 h post-training; administration
immediately after training required the lowest dose, suggest-
ing a primary effect on early memory consolidation rather
than acquisition (Prickaerts et al. 2004, 2005). In a placebo-
controlled trial in healthy young men, sildenafil 100 mg
Fig. 1 Phosphodiesterase 5 (PDE5) inhibitors are believed to enhance
memory and learning via facilitation of long-term potentiation (LTP)
mediated by the “glutamate–nitric oxide–cyclic GMP intracellular
pathway.” Glutamate binding to the N-methyl-D-aspartate (NMDA)
receptor results in calcium (Ca2+) influx, which binds to calmodulin
and activates nitric oxide synthase (NOS). NOS catalyzes the
production of nitric oxide (NO) from arginine; NO activates guanylyl
cyclase, which increases production of cyclic guanosine monophos-
phate (GMP) from guanosine triphosphate (GTP). Cyclic GMP
mediates LTP and activates protein kinases (PK), which are believed
to mediate memory consolidation via phosphorylation and protein
formation. PDE5 inhibitors block the conversion of cGMP to 5′GMP;
by elevating cGMP levels, LTP is facilitated
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significantly affected patterns of event-related potentials
consistent with enhanced ability to focus attention and to
select relevant target stimuli, although actual performance
did not significantly improve (Schultheiss et al. 2001).
Sildenafil was safe and effective when administered to male
schizophrenia patients for erectile dysfunction in two studies
(Aviv et al. 2004; Gopalakrishnan et al. 2006).
We conducted a double-blind, placebo-controlled, random-
order, single-dose crossover trial of sildenafil 50 and 100 mg
added to stable antipsychotic treatment in schizophrenia
patients to assess whether this PDE5 inhibitor improves
cognitive functioning and clinical symptoms.
Materials and methods
Subjects were adult outpatients with schizophrenia recruited
from a community mental health center and were clinically
stable without a medication change for at least 4 weeks.
Subjects had to be English speaking, be medically stable
without cardiac disease, and free of substance abuse or
dependence for at least 3 months. Patients were excluded if
they were currently taking drugs that inhibit or induce
hepatic cytochrome P450 3A4, nitrates, alpha blockers, or
PDE5 inhibitors. Subjects could not be pregnant or have a
history of priapism or inappropriate sexual behavior.
After providing written informed consent, patients met
with a research psychiatrist to verify the diagnosis of
schizophrenia by Diagnostic and Statistical Manual of
Mental Disorders IV criteria and to review the medical
history. A physical examination and vital signs were
performed, and an electrocardiogram was obtained. Women
of reproductive age were given a pregnancy test and
counseled regarding use of appropriate birth control methods.
After the diagnosis had been confirmed and the patient
had been medically cleared by the research psychiatrist,
patients were scheduled for three sessions separated by
2 days. The order of study drug (sildenafil 50 mg, 100 mg,
or placebo) was randomly assigned in a 1:1:1 ratio. Placebo
and sildenafil were administered in identical-appearing
capsules. Subjects continued to take all psychiatric medi-
cations without change during the course of the study. At
baseline, the brief psychiatric rating scale (BPRS) was
completed, and the cognitive battery was administered. In
order to test memory consolidation, subjects returned
2 days later and were tested for a 48-h delayed recall of
the Hopkins verbal learning test (HVLT) and logical
memory test (LMT) that had been administered as part of
the cognitive battery 2 days earlier. After blood pressure
and pulse (sitting and standing) were measured, subjects
were administered a single oral dose of the study drug.
Starting 1 h after ingestion of the study drug, blood
pressure, pulse, and self-reported side effects were recorded.
The BPRS and cognitive battery were then repeated. Blood
pressure and pulse were recorded again 2 h after administra-
tion of the study drug. Subjects completed three identical
postbaseline sessions and returned 48 h after each session for
testing of delayed recall.
The cognitive battery assessed five cognitive domains
and included the following tests: the HVLT (Benedict et al.
1998) using counterbalanced word lists to assess verbal
learning, Letter–Number Sequencing (Wechsler Adult
Intelligence Scale [WAIS]-III, The Psychological Corporation)
and Digit Symbol (WAIS-III, The Psychological Corporation)
to assess processing speed, category fluency to assess semantic
fluency (Benton and Hamsher 1978), the continuous perfor-
mance test—identical pairs to assess attention and vigilance,
and Spatial Span (WechslerMemory Scale III) to assess spatial
memory. A summary score was derived for each test using the
standardized z score for the single item or mean for that test
rectified so that a positive change in z score represents im-
proved performance. A composite cognitive score was
calculated from the mean of these five z scores. In addition,
to assess memory consolidation, recall was tested after a 48-
h delay following administration of the HVLT to test verbal
memory and the LMT (story A) from the Revised Wechsler
Memory Scale (Wechsler 1997) to test verbal thematic recall.
Statistical analysis
The analysis was based on intent-to-treat and included all 17
randomized subjects. Differences in baseline and demographic
variables were assessed using Student’s t test and Chi-square
or Fisher’s exact test. The primary outcome measure was
change in composite cognitive score from baseline. Second-
ary outcome measures included change from baseline in each
of the five cognitive domains, BPRS total, BPRS negative
symptom subscale, BPRS depression item, and 48-h delayed
performance on the HVLT and LMT. For these variables,
analysis of covariance were performed to determine differ-
ences between placebo, sildenafil 50 and 100 mg, controlling
for order (PROC GLM). All analyses were performed using
SAS. An alpha of 0.05 was used to determine significance,
and because of the exploratory nature of this study, a
correction was not made for multiple comparisons.
Results
Eighteen patients were enrolled, 17 were randomized, and
15 completed all three treatment conditions. One subject
dropped out after the first treatment session (placebo), and
one was dropped from study 2 days after the first treatment
session (sildenafil 100 mg) due to irritability; this patient
was subsequently hospitalized. The mean age of completers
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was 49.7 years (SD=0.6). Eight subjects (47%) were male.
Twelve of the 17 subjects (71%) were Caucasian, four
subjects (24%) were African-American, and one subject
(6%) was Hispanic. Five subjects were treated with
olanzapine, two with clozapine, two with aripiprazole, two
with conventional antipsychotics, two with risperidone, one
with quetiapine, and three with combination (quetiapine
and fluphenazine, olanzapine and ziprasidone, and perphe-
nazine and ziprasidone).
There was no significant main effect of study medication
on change in composite cognitive score from baseline.
Additionally, a main effect of study medication was not
found for any of the secondary outcome measures. Effect
sizes of study drug for cognitive domains ranged from 0.07
(small) to 0.61 (large), and in each comparison, performance
improved more (or worsened less) with placebo compared to
sildenafil. Effect sizes for the Positive and Negative Syn-
drome Scale (PANSS) total and PANSS subscale scores were
all small (0.00–0.21) and also favored placebo.
Side effects
Sildenafil was generally well tolerated, although one
dropout due to irritability occurred following administration
of sildenafil 100 mg. One subject reported moderate
sedation 1 h after the sildenafil 100-mg dose. Two subjects
exhibited drops in diastolic blood pressure of 7 and
Table 1 Mean change scores from baseline to poststudy drug administration
Placebo Sildenafil 50 mg ES Sildenafil 100 mg ES F value p value
Symptoms
BPRSa
Positive symptom total 0.06±0.25 0.40±1.30 0.21 0.06±0.25 0.00 0.01 0.99
Negative symptom total −0.15±0.54 −0.16±0.67 0.02 −0.08±0.71 0.14 0.08 0.93
Depression item −0.06±0.25 0.00±0.00 0.06 0.00±0.00 0.06 0.04 0.96
Total −0.19±1.22 −0.20±0.56 0.00 −0.06±0.57 0.03 0.30 0.74
Cognitive testsb
HVLT
Total recall −0.50±5.05 −0.87±4.00 0.08 −1.50±4.58 0.22 0.19 0.83
Delayed (48 h) recall −1.53±2.45 −1.27±1.98 0.11 −2.07±2.55 0.23 0.44 0.64
Letter number
Without reordering 0.56±1.86 0.47±1.19 0.05 0.44±1.75 0.07 0.02 0.98
With reordering 0.13±1.54 −0.40±1.68 0.33c 0.00±1.55 0.08 0.45 0.64
Digit symbol total 7.19±8.42 3.20±7.05 0.49c 5.63±9.06 0.19 0.93 0.40
Animals: total 3.69±3.65 2.60±3.27 0.31c 3.00±3.46 0.20 0.39 0.68
CPT−IP
2 d′ 0.24±0.69 0.05±0.86 0.26 0.02±0.62 0.30c 0.38 0.68
3 d′ 0.25±0.83 0.34±0.92 0.11 0.26±0.81 0.01 0.04 0.96
4 d′ 0.50±0.57 0.18±0.67 0.54c 0.28±0.53 0.37c 1.11 0.34
Spatial span
Forward −0.06±1.69 −0.14±1.23 0.05 −0.38±1.63 0.21 0.17 0.84
Reverse 0.94±1.65 0.57±1.74 0.22 0.63±1.63 0.19 0.22 0.80
Logical memory—thematic
Immediate 0.94±1.12 0.80±1.78 0.10 0.81±1.33 0.09 0.05 0.95
Delayed (48 h) 2.27±1.71 1.80±1.90 0.29 2.20±1.61 0.04 0.36 0.70
Logical memory—unit
Immediate 3.56±2.85 2.87±3.83 0.22 3.38±3.26 0.06 0.21 0.81
Delayed (48 h) 6.13±4.60 5.80±5.62 0.07 6.33±5.34 0.04 0.05 0.95
Cognitive domains (z scores)b
Verbal memory −0.01±1.06 −0.08±0.84 0.07 −0.22±0.97 0.22 0.19 0.83
Working memory −0.05±0.30 −0.23±0.23 0.61d −0.12±0.34 0.24 1.47 0.24
Semantic fluency 0.02±0.61 −0.18±0.58 0.34c −0.10±0.61 0.20 0.46 0.63
Attention 0.06±0.43 −0.12±0.49 0.38c −0.12±0.51 0.38c 0.71 0.50
Spatial memory −0.01±0.68 −0.11±0.46 0.17 −0.15±0.53 0.24 0.25 0.78
Cognitive composite (z scores) 0.00±0.32 −0.13±0.33 0.40c −0.14±0.33 0.43c 0.95 0.39
a Positive change from baseline reflects worsening/negative change from baseline reflects improvement in measure
b Positive change from baseline reflects improvement/negative change from baseline reflects worsening in measure
cMedium effect size
d Large effect size
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14 mmHg after sildenafil 100 mg; in both cases, the
systolic blood pressure did not drop, and the subject
remained asymptomatic. Reports of dizziness were not
more common with sildenafil compared to placebo, and no
headaches or visual disturbances were reported (Table 1).
Discussion
Our hypothesis, that sildenafil would improve cognition
when added to antipsychotics in patients with schizophrenia,
was not supported. The explanation for this negative finding
is uncertain. It is possible that the potential effect is too small
to detect in a sample of this size. It is also possible that both
doses of sildenafil administered in this study were outside an
effective dose range. Studies in rats have identified an inverted
U-shaped dose–response relationship with an optimal dose of
1–10 mg/kg. In an object recognition task in rats,
sildenafil improved memory when administered at a dose
of 3 mg/kg immediately after training, whereas a dose of
10 mg/kg was required when administered 30 min prior to
training. The increase in minimum effective dose was
attributed to the rapid metabolism of sildenafil (half-life of
0.4 h) necessitating a higher dose to achieve adequate
brain concentrations during the period of cGMP-dependent
memory consolidation (Prickaerts et al. 2004). The half-life of
sildenafil in humans is 4 h, suggesting that administration
1 h prior to cognitive testing should not be complicated by
the rapid clearance observed in rats (Boolell et al. 1996).
Because sildenafil readily crosses the blood–brain barrier, the
doses administered in this study would be expected to
substantially inhibit brain PDE5. It is possible that repeated
dosing may be required to produce cognitive or behavioral
effects. In animal studies, cognitive effects have been demon-
strated with both single and repeated dosing. Daily dosing with
sildenafil has not been studied in schizophrenia, although this
approach has been utilized successfully in the treatment of
pulmonary hypertension (Chockalingam et al. 2005).
Sildenafil was generally well tolerated, although one
subject experienced irritability following sildenafil 100 mg.
While it is unclear whether this dysphoric response resulted
from study drug, rare reports of central nervous system
adverse effects have been reported, including aggression
and amnesia (Milman and Arnold 2002). In addition,
increased aggression was observed in mice 1 week after
discontinuation of a 4-week regimen of high-dose sildenafil
administered three times weekly (Hotchkiss et al. 2005).
However, no worsening of psychiatric symptom ratings was
observed in a 6-week open trial of sildenafil 25–75 mg
administered as needed to 12 schizophrenia patients with
erectile dysfunction (Aviv et al. 2004).
A large literature has implicated dysregulation of
neuronal NOS in schizophrenia (Bernstein et al. 2005).
Evidence suggesting abnormalities in this intermediate step
of the NMDA/NO/cGMP pathway include linkage of the
carboxyl-terminal PDZ-ligand of nNos (CAPON) to schizo-
phrenia (Eastwood 2005), altered concentrations of NO and
NO metabolites in blood and cerebrospinal fluid, and, in
postmortem brain, abnormalities in the cortical distribution
of neuronal NOS (nNOS)-expressing neurons (Akbarian
et al. 1993), nNOS ribonucleic acid expression, and nNOS
activity (Bernstein et al. 2005). However, the complexity of
findings makes it difficult to predict whether dysregulation
of NO is primarily in the direction of an increase or decrease.
In addition, haloperidol and chlorpromazine but not second-
generation antipsychotics, decrease nNOS activity in rats (Nel
and Harvey 2003; Tarazi et al. 2002). Deutsch et al. (1997)
reported an improvement in psychopathology ratings with
the NOS inhibitor, methylene blue, in a pilot study of eight
antipsychotic-refractory schizophrenia patients.
Whereas evidence for dysregulation of nNOS in schizo-
phrenia supports pharmacological targeting of the NMDA/
NO/cGMP pathway, it is possible that an underlying
impairment of function in this pathway could result in
reduced or absent cognitive enhancement with PDE5
inhibition. PDE5 inhibition amplifies the signal generated
by NMDA receptor activation and NO release; cGMP
levels will not increase if this pathway is not intact. Studies in
healthy, medication-free subjects are needed to assess whether
the encouraging findings of cognitive enhancement in animal
models can be translated to humans. The one published study
of sildenafil in healthy subjects produced ambiguous results;
electrophysiologic measures of concentration improved,
whereas performance did not (Schultheiss et al. 2001). In
addition, inhibitors of other subtypes of PDE may be more
effective in producing cognitive effects in humans. PDE4
inhibitors are currently being developed for cognitive
disorders, and PDE10 inhibitors are under study for the
treatment of schizophrenia (Bender and Beavo 2006).
Conclusion
Despite an animal literature demonstrating cognitive-
enhancing effects of sildenafil and a rationale for sildenafil
as a strategy for facilitating NMDA receptor-mediated
effects on memory by targeting intracellular pathways
downstream from NMDA receptors, we did not detect
effects of a single dose of sildenafil 50 and 100 mg on a
traditional cognitive battery, nor did we find evidence for
improved memory consolidation when recall was tested
after 48 h. Symptoms of schizophrenia also did not
improve. It is possible that the doses used in this study
were not optimal, that repeated dosing may be necessary to
achieve therapeutic effects, or that PDE5 inhibition is not a
viable strategy in medicated schizophrenia patients. Additional
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studies of alternative dosing strategies in healthy subjects may
provide some clarification. Agents under development that
inhibit other subtypes of PDE remain promising.
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